NCT05397392 Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
| NCT ID | NCT05397392 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2016-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2016-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
Eligibility Criteria
Inclusion Criteria: Patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney. Exclusion Criteria: Pregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05397392 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05397392 currently recruiting?
Yes, NCT05397392 is actively recruiting participants. Contact the research team at 56005460@qq.com for enrollment information.
Where is the NCT05397392 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05397392 clinical trial?
NCT05397392 is sponsored by Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.